February 23, 2026
ROME & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development.
EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Compai Pharma to Commercialize BINOSTO® in Malaysia
Freienbach, January 8th 2026 – EffRx Pharmaceuticals SA, a Swiss commercial-stage pharmaceutical company focused on the development and commercialization of treatments for endocrine, metabolic and musculoskeletal disorders, today announced the signing of an exclusive licensing and distribution agreement with Compai Pharma for the commercialization of Binosto® in Malaysia. Compai Pharma is a leading medical distribution company with strong reach across South East Asia.
Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Quiver Bioscience (“Quiver”) and QurAlis Corporation (“QurAlis”), today announced that the companies have entered into a research collaboration to advance a novel gene-targeted therapeutic approach for the treatment of Fragile X syndrome (FXS). The goal of the collaboration is to combine Quiver’s unique “Genomic Positioning System” (GPS) drug discovery platform with QurAlis’ expertise in developing next-generation precision medicines for neurodegenerative and neurological diseases to build a foundational data package in support of advancing a potentially transformative therapeutic for FXS.
[Read more…] about Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome